Back to top

UBS Keeps Their Buy Rating on BeOne Medicines Ltd (6160)

In a report released on August 10, from UBS maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$280.20. The company’s shares ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)